Telomir Pharmaceuticals Q2 2025 Earnings Report

Telomir Pharmaceuticals EPS Results

• Actual EPS: -$0.17
• Consensus EPS: -$0.08
• Beat/Miss: Missed by -$0.09
• One Year Ago EPS: N/A

Telomir Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Telomir Pharmaceuticals Announcement Details

• Quarter: Q2 2025
• Date: 8/14/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Telomir Pharmaceuticals (NASDAQ:TELO) (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling. In parallel, Telomir maintains a preclinical pipeline of compounds designed to act on distinct molecular targets with the goal of delivering differentiated safety and efficacy profiles. Collaborative partnerships with academic institutions and contract research organizations support translational research efforts and accelerate compound progression from discovery through early clinical evaluation.

Headquartered in the United States, Telomir Pharmaceuticals is guided by an executive team with extensive experience in biopharmaceutical research, clinical development and regulatory affairs. While the company’s initial focus is on advancing its lead programs through clinical milestones in North America, management has articulated plans to pursue strategic alliances that could enable broader international development and commercialization. As a Nasdaq-listed entity, Telomir continues to refine its pipeline and expand its scientific platform with the goal of delivering innovative therapies to patients around the world.